Let's Cure AML Together and Open a New Future for Cancer Care
Whenever I talk about Nemucore Medical Innovations, I’m often met with the same response: “My wife/father/brother had cancer." It’s pervasive and heartbreaking. Many of these wives, fathers, and brothers have gone on to lead full lives; many others have not. Each cancer is unique, and the treatment that works for one person may not work for another. When I founded Nemucore Medical Innovations, I was driven by one principle: match the right treatment with the right patient.
The first cancer treatments on the market were designed to indiscriminately kill everything. This meant that, though cancer cells would be eliminated, so would healthy cells. What use is a treatment if it kills you in the process?
Luckily, medicine has evolved since then. Cancer patients have more hope of finding a treatment that fits their specific cancer, especially if their cancer contains a specific mutation that makes it easy to target. Unfortunately, not all cancers contain mutations that can be targeted. This is especially true of certain blood cancers, where a majority of patients lack “actionable” mutations. Nemucore Medical Innovations has set out to create patient-specific treatment that work in patients with Acute Myeloid Leukemia (AML) and high-risk Myelodysplastic Syndromes (hrMDS) where the lack of “actionable” mutations is particularly high.
Our method consists of a two-pronged approach. First, we test the RNA of a patient’s cancer. While most cancer diagnostics focus on the DNA of a cell, our approach uses RNA because it is the richest source of information in a cancer cell. We use the information found within RNA to determine if a patient’s cancer will be sensitive to our drug, NMI-900. If a patient’s cancer is not sensitive to NMI-900, we know that this patient is not a good match for our drug. By running a diagnostic test first, physicians can treat only those patients who will benefit from our drug, and not subject patients to treatment plans that will not work for them. Then, NMI-900 will be administer to only those patients who will benefit. NMI-900 does not rely on a mutation to work, but instead works by halting the rapid division of cancer cells.
Our drug and diagnostic combination has been well received by world-leading clinicians at major hospitals, who have enthusiastically agreed to conduct our groundbreaking clinical study. They believe, as I do, that each cancer deserves a unique treatment to create the best possible outcome for the patient. My belief in this has only deepened as I, too, have my own story of how cancer has touched my life. In 2016, my sister was diagnosed with a cancer that did not have a "druggable" mutation that could be matched to a treatment. She is one of the lucky ones; her cancer responded to trtreatments that currently exist.
The opportunity to invest in Nemucore Medical Innovations is an opportunity to help individuals who are not so lucky. We invite anyone whose lives have been touched by cancer – be it a family member, a friend, or even if you are a survivor – to own a piece of what we hope is a solution for patients without a treatment that matches their cancer.
Thank you in advance,
Tim Coleman, Founder and CEO
Bringing Our New Drug to Patients With Acute Myeloid Leukemia
We're developing 1) a best-in-class drug for a highly lethal type of blood cancer and 2) a companion diagnostic to determine which patients will respond well to this drug. The diagnostic tests if a patient's cancer is sensitive or resistant to our drug by focusing on RNA of the cancer rather than DNA. We're currently preparing for Phase 1b/2 of clinical trials. If successful, we could improve survival and quality of life for tens of thousands of patients with cancer.
AML is a highly lethal cancer that starts in the bone marrow and causes patients to become very ill.
Join Us in Completing The Final Clinical Studies to Help Patients with AML
We founded Nemucore with a mission to develop targeted medicines for cancers that lack "druggable" mutations.
Cancer Research United Kingdom (CRUK) Begins Phase 1 Trial
Received Five-Year National Cancer Institute Grant
R01 grant awarded to further our mission.
Phase 1 Trial Successfully Completed
Trial showed that NMI-900 was safe and had clinical activity in 22/36 of patients.
NMI-900 Preclinical Trial in Blood Cancer
Showed NMI-900 preclinical blood cancer model was effective using new dose.
NMI-900 Preclinical Trial as Combination Therapy in Ovarian and Lung Cancer
Trial showed NMI-900 is effective in this capacity.
Recruited Clinical Partners at Moffitt and Memorial Sloan Kettering
Together, we designed and drafted a Phase 1b/2 clinical trial protocol.
Expected Interim Data Analysis
Data from first cohort of patients treated in Phase 1b Clinical Trial of NMI-900; results from retrospective data analysis of NMI-900 companion diagnostic.